Torpedo

Affini-T Therapeutics is a clinical-stage biotechnology company focused on developing next-generation TCR-engineered T cell therapies (TCR-T) for patients with solid tumors. The company leverages its proprietary platform to target core oncogenic drivers, specifically focusing on mutations in KRAS, which are prevalent in many hard-to-treat cancers like pancreatic, colorectal, and lung cancer. Founded by pioneers in the field of immunotherapy, Affini-T aims to overcome the immunosuppressive tumor microenvironment through synthetic biology and advanced cell engineering. Their pipeline includes programs targeting KRAS G12V and G12D mutations, currently undergoing clinical evaluation. The company was originally established as Torpedo Therapeutics before rebranding to its current name in 2022.